Aprea AB

Aprea’s drug candidate has anti-tumor effects and may also fulfill an unmet need by overcoming resistance to several conventional chemotherapeutic drugs.

Aprea has found a unique way of putting defective p53 back into shape. Aprea’s drug candidate APR-246 reactivates both mutant and defective native p53, leading to tumor cell death. This also raises hopes for improving the efficacy of chemotherapy. Initial clinical trials have shown good safety and significant biological and clinical effects.

Kategorier: Pharma

Gå till Aprea ABs hemsida